Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients
Enrolling by invitationOBSERVATIONAL
Enrollment
900
Participants
Timeline
Start Date
May 22, 2018
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2026
Conditions
Cancer
Trial Locations (1)
20892
National Institutes of Health Clinical Center, Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT02706652 - Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients | Biotech Hunter | Biotech Hunter